Breaking news in heart failure: ESC Guidelines 2016, non-steroidal mineralocorticoid receptor antagonist, and alternate site CRT pacing

被引：0
|
作者：
Luescher, Thomas F. [1 ]
机构：
[1] Zurich Heart House,Careum Campus,Moussonstr 4, CH-8091 Zurich, Switzerland
来源：
EUROPEAN HEART JOURNAL | 2016年 / 37卷 / 27期
关键词：
CARDIOVASCULAR RISK; OUTCOMES; ASSOCIATION; EPLERENONE; FINERENONE;
D O I：
10.1093/eurheartj/ehw306
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：2085 / 2087
页数：3
相关论文
共 45 条
  • [21] Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease (vol 18, pg 28, 2016)
    Bramlage, Peter
    Swift, Stephanie L.
    Thoenes, Martin
    Minguet, Joan
    Ferrero, Carmen
    Schmieder, Roland E.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (06) : 811 - 811
  • [22] Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys
    Yamada, Makiko
    Takei, Makoto
    Suzuki, Eiko
    Takakusa, Hideo
    Kotsuma, Masakatsu
    Washio, Takuo
    Murayama, Nobuyuki
    Inoue, Shin-ichi
    Izumi, Takashi
    XENOBIOTICA, 2017, 47 (12) : 1090 - 1103
  • [23] Improved survival and nephroprotection in hypertensive rats by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist
    Kolkhof, P.
    Kretschmer, A.
    Baerfacker, L.
    Hartmann, E.
    Schaefer, S.
    EUROPEAN HEART JOURNAL, 2012, 33 : 978 - 979
  • [24] Effects Of Finerenone - A Novel Non-steroidal Mineralocorticoid Receptor Antagonist In A Model Of Pressure Overload-induced Cardiac Hypertrophy
    Grune, Jana
    Benz, Verena
    Brix, Sarah
    Ban, Zsofia
    Salatzki, Janek
    Hoeft, Beata
    Foryst-Ludwig, Anna
    Klopfleisch, Robert
    Kolkhof, Peter
    Kintscher, Ulrich
    HYPERTENSION, 2014, 64
  • [25] Effects of Finerenone - a novel non-steroidal mineralocorticoid receptor antagonist in a model of pressure overload-induced cardiac hypertrophy
    Grune, J.
    Benz, V
    Brix, S.
    Ban, Z.
    Janek, S.
    Foryst-Ludwig, A.
    Klopfleisch, R.
    Kolkhof, P.
    Kintscher, U.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 : S35 - S35
  • [26] THE NON-STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONIST, FINERENONE, REDUCES VASCULAR PATHOLOGY AND INFLAMMATION IN PRE-CLINICAL DIABETIC RETINOPATHY
    Jerome, Jack Ryan
    Suphapimol, Vara
    Delayanti, Devy
    Jayasimhan, Abhirup
    Kolkhof, Peter
    Wilkinson-Berka, Jennifer
    JOURNAL OF HYPERTENSION, 2023, 41 : E280 - E280
  • [27] Non-steroidal aldosterone receptor antagonism: a 'fine' treatment for heart failure patients? COMMENT
    Asleh, Rabea
    Briasoulis, Alexandros
    Borlaug, Barry A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (06) : 1006 - 1008
  • [28] Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist
    Di Lullo, Luca
    Lavalle, Carlo
    Scatena, Alessia
    Mariani, Marco Valerio
    Ronco, Claudio
    Bellasi, Antonio
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (12)
  • [29] The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease
    Barrera-Chimal, Jonatan
    Gerarduzzi, Casimiro
    Rossignol, Patrick
    Jaisser, Frederic
    CLINICAL SCIENCE, 2022, 136 (12) : 1005 - 1017
  • [30] SM-368229, a Novel Selective and Potent Non-steroidal Mineralocorticoid Receptor Antagonist With Strong Urinary Na+ Excretion Activity
    Nariai, Tetsuro
    Fujita, Katsuya
    Mori, Masaya
    Katayama, Seiji
    Hori, Seiji
    Matsui, Kazuki
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 (03) : 346 - 353
12345